NCT00626223View on ClinicalTrials.gov

5-methyltetrahydrofolate Survival and Inflammation in ESRD Patients

NACompletedINTERVENTIONAL
Enrollment

341

Participants

Timeline

Start Date

January 31, 1998

Primary Completion Date

July 31, 2001

Study Completion Date

July 31, 2007

Conditions
MortalityHyperhomocysteinemiaInflammation
Interventions
DRUG

5-MTHF (5-methyltetrahydrofolate)

50 mg intravenous at the end of each hemodialysis session

DRUG

folic acid

5 mg per day of oral folic acid

Trial Locations (1)

40138

Nephrology Dialysis and Renal Transplantation Unit, S.Orsola University Hospital, Bologna

All Listed Sponsors
collaborator

University of Bologna

OTHER

lead

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER

NCT00626223 - 5-methyltetrahydrofolate Survival and Inflammation in ESRD Patients | Biotech Hunter | Biotech Hunter